The objective of the Biostatistics and Research Information Shared Resource is to provide collaborative and consultative services to Stanford Cancer Center investigators and thereby add value in all phases of cancer research. Capabilities include high-quality biostatistics consultation on the use of standard methods as well as innovation in developing methods specifically to enhance the basic and translational research efforts of a discovery-oriented Cancer Center faculty. As a dedicated core with a clear means of access, the Biostatistics Shared Resource greatly benefits those researchers in need of statistical collaboration and consultation in their studies. Since official inception of this Shared Resource in 2005, more than 200 Cancer Center members representing all ten Research Programs have been assisted through the Biostatistics Shared Resource. Significant additional contributions by staff in this Shared Resource include new methods in microarray data analysis and genetic association studies, as well as innovative designs for clinical trials. The core also advises on strategic issues with statistical content, such as criteria for scientific review and development of databases and registries. It provides support to the Northern California Cancer Center, with a dedicated on site senior biostatistician staff member who is responsible for first point of contact and access to the entire Resource. The Shared Resource has responsibility for supporting the development of a Research Database for the Cancer Center, an effort that is currently underway, using methods that have been successfully deployed in two landmark programs (Lymphoma and Hematopoetic Cell Transplant) in the Cancer Center. The Shared Resource is also responsible for caBIG ? activities at Stanford.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475467
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$175,586
Indirect Cost
$3
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications